Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul-Sep;52(3):297-8.
doi: 10.4103/0019-509X.176735.

Eribulin mesylate in Indian patients: A single center experience

R Thippeswamy, S Patil  1 , H P Shashidara, C T Satheesh, H Vittal, S Mishra
Affiliations
Free article

Eribulin mesylate in Indian patients: A single center experience

R Thippeswamy et al. Indian J Cancer. 2015 Jul-Sep.
Free article

Abstract

Background: Eribulin mesylate is the latest addition in the armamentarium of management of metastatic breast cancer (MBC) with a unique mechanism of action. Although the multicentric EMBRACE trial suggests significant overall survival benefit from this novel drug, its effectiveness in Indian population is yet to be evaluated.

Materials and methods: Presented here is a single center experience of eight patients who were administered eribulin for MBC. Patients had received a median of 3 prior chemotherapies before eribulin administration. The median dose of eribulin therapy was 5 cycles (range: 2-6 cycles).

Results: The objective response rate was 75% (CR in one and PR in five out of eight patients). Response was seen across all subtypes of patients. Eribulin was well tolerated. No serious adverse events were reported.

Conclusion: Eribulin conferred good response rates with satisfactory tolerability profile in Indian patients. Its use in earlier lines and in combination with other drugs may achieve deeper and longer responses.

PubMed Disclaimer

LinkOut - more resources